,i #aaith ,,congress #ast ,session ,h4 ,r4 #adje ,,in ,,the ,,house ,,of ,,representatives ,february #ah1 #bjbe,mr4 ,buchanan 7for himself and ,mr4 ,donalds7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to direct the ,comptroller ,general of the ,united ,states to conduct a study to assess the key regulatory barriers that impede the expansion or siting of new pharmaceutical manufacturing facilities in the ,united ,states1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,enhancing ,domestic ,drug ,manufacturing ,competitiveness ,act4 #b4 ,study on key regulatory barriers to expanding pharmaceutical manufacturing in the ,united ,states 7a7 ,in general ,the ,comptroller ,general of the ,united ,states shall conduct a study to identify1 and to assess on a time and cost basis1 the key regulatory barriers that-- 7#a7 impede the expansion or siting of new pharmaceutical manufacturing facilities in the ,united ,states2 or 7#b7 make the ,united ,states less competitive than other countries as a location for such facilities4 7b7 ,questions ,in conducting the study under subsection 7a71 the ,comptroller ,general shall consider the following questions3 7#a7 ,do environmental or other regulations significantly delay1 and increase the costs for manufacturers of1 expanding or siting pharmaceutical manufacturing facilities in the ,united ,states relative to environmental or other regulations in other countries8 7#b7 ,what is the potential impact of environmental and other regulations on pharmaceutical supply chain resiliency8 7#c7 ,what specific actions 7such as expediting reviews1 inspections1 and approvals of new facilities or changes to existing facilities7 could be taken by regulators to address the regulatory barriers described in subsection 7a78 7c7 ,engaging stakeholders ,in conducting the study under subsection 7a71 the ,comptroller ,general shall engage stakeholders-- 7#a7 to identify and assess the barriers described in subsection 7a72 7#b7 to identify whether there are promising technological solutions1 including manufacturing processes1 that could help to address the regulatory barriers described in subsection 7a72 and 7#c7 to identify the policies needed to support and foster any solutions identified pursuant to paragraph 7#b74 7d7 ,report 7#a7 ,in general ,not later than #a year after the date of enactment of this ,act1 the ,comptroller ,general shall complete the study under subsection 7a7 and submit to the ,congress a report on the results of such study4 7#b7 ,contents ,the report required by paragraph 7#a7 shall-- 7,a7 identify1 and assess on a time and cost basis1 the regulatory barriers described in subsection 7a72 7,b7 address each question listed in subsection 7b72 and 7,c7 include recommendations for streamlining the regulatory barriers described in subsection 7a71 and facilitating the use of technological solutions described in subsection 7c77#b71 to foster increased pharmaceutical manufacturing in the ,united ,states4